Quest PharmaTech Inc. (CVE:QPT – Get Free Report) shares reached a new 52-week low during trading on Friday . The stock traded as low as C$0.02 and last traded at C$0.02, with a volume of 5500 shares changing hands. The stock had previously closed at C$0.03.
Quest PharmaTech Trading Down 20.0%
The company has a quick ratio of 0.52, a current ratio of 0.40 and a debt-to-equity ratio of 4.35. The business’s fifty day moving average is C$0.03 and its two-hundred day moving average is C$0.03. The firm has a market cap of C$3.38 million, a price-to-earnings ratio of 0.67 and a beta of -0.07.
About Quest PharmaTech
Quest PharmaTech Inc, a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer. In addition, it develops, manufactures, and commercializes immunotherapy products for pancreatic cancer; and combinatorial immunotherapeutic products for the treatment cancer by using monoclonal antibodies of the immunoglobulin of G and E class.
Further Reading
- Five stocks we like better than Quest PharmaTech
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Receive News & Ratings for Quest PharmaTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest PharmaTech and related companies with MarketBeat.com's FREE daily email newsletter.
